1
|
Balk MA, Deck J, Emery KF, Walls RL, Reuter D, LaFrance R, Arroyo-Cabrales J, Barrett P, Blois J, Boileau A, Brenskelle L, Cannarozzi NR, Cruz JA, Dávalos LM, de la Sancha NU, Gyawali P, Hantak MM, Hopkins S, Kohli B, King JN, Koo MS, Lawing AM, Machado H, McCrane SM, McLean B, Morgan ME, Pilaar Birch S, Reed D, Reitz EJ, Sewnath N, Upham NS, Villaseñor A, Yohe L, Davis EB, Guralnick RP. A solution to the challenges of interdisciplinary aggregation and use of specimen-level trait data. iScience 2022; 25:105101. [PMID: 36212022 PMCID: PMC9535407 DOI: 10.1016/j.isci.2022.105101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 03/23/2021] [Accepted: 07/27/2022] [Indexed: 11/28/2022] Open
Abstract
Understanding variation of traits within and among species through time and across space is central to many questions in biology. Many resources assemble species-level trait data, but the data and metadata underlying those trait measurements are often not reported. Here, we introduce FuTRES (Functional Trait Resource for Environmental Studies; pronounced few-tress), an online datastore and community resource for individual-level trait reporting that utilizes a semantic framework. FuTRES already stores millions of trait measurements for paleobiological, zooarchaeological, and modern specimens, with a current focus on mammals. We compare dynamically derived extant mammal species' body size measurements in FuTRES with summary values from other compilations, highlighting potential issues with simply reporting a single mean estimate. We then show that individual-level data improve estimates of body mass—including uncertainty—for zooarchaeological specimens. FuTRES facilitates trait data integration and discoverability, accelerating new research agendas, especially scaling from intra- to interspecific trait variability. Functional Trait Resource for Environmental Studies (FuTRES; few-tress) Individual-level trait datastore for paleo-, zooarcheological, and modern specimens Millions of individual-level trait data records already available for mammals Semantic framework for enhanced interoperability, R package for access, and APIas
Collapse
Affiliation(s)
- Meghan A. Balk
- National Ecology Observatory Network, Battelle, Boulder, CO 80301, USA
- Smithsonian Institution, National Museum of Natural History, Washington, DC 20560, USA
- Corresponding author
| | - John Deck
- Berkeley Natural History Museums, University of California, Berkeley, Berkeley, CA 94720, USA
- Biocode LLC, Junction City, OR 97448, USA
| | - Kitty F. Emery
- Florida Museum of Natural History, University of Florida, Gainesville, FL 32611, USA
| | - Ramona L. Walls
- Critical Path Institute, Tucson, AZ 85718, USA
- BIO5 Institute, University of Arizona, Tucson, AZ 85719, USA
| | - Dana Reuter
- Department of Earth Sciences, University of Oregon, Eugene, OR 97403, USA
| | - Raphael LaFrance
- Florida Museum of Natural History, University of Florida, Gainesville, FL 32611, USA
| | - Joaquín Arroyo-Cabrales
- Archaeozoology Lab, Instituto Nacional de Antropologia e Historia, 06060 Mexico City, CdMx, Mexico
| | - Paul Barrett
- Department of Earth Sciences, University of Oregon, Eugene, OR 97403, USA
| | - Jessica Blois
- Department of Life and Environmental Sciences, University of California, Merced, Merced, CA 95343, USA
| | - Arianne Boileau
- Department of Archaeology, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
| | - Laura Brenskelle
- Department of Biology, University of Florida, Gainesville, FL 32611, USA
| | - Nicole R. Cannarozzi
- Florida Museum of Natural History, University of Florida, Gainesville, FL 32611, USA
| | - J. Alberto Cruz
- Archaeozoology Lab, Instituto Nacional de Antropologia e Historia, 06060 Mexico City, CdMx, Mexico
| | | | - Noé U. de la Sancha
- Department of Environmental Science and Studies, DePaul University, Chicago, IL 60614, USA
- Negaunee Integrative Research Center, The Field Museum of Natural History, Chicago, IL 60605, USA
| | | | - Maggie M. Hantak
- Florida Museum of Natural History, University of Florida, Gainesville, FL 32611, USA
| | - Samantha Hopkins
- Department of Earth Sciences, University of Oregon, Eugene, OR 97403, USA
- Museum of Natural and Cultural History, University of Oregon, Eugene, OR 97401, USA
| | - Brooks Kohli
- Department of Biology and Chemistry, Morehead State University, Morehead, KY 40351, USA
| | - Jessica N. King
- Florida Museum of Natural History, University of Florida, Gainesville, FL 32611, USA
| | - Michelle S. Koo
- Museum of Vertebrate Zoology, University of California, Berkeley, Berkeley, CA 94720, USA
| | - A. Michelle Lawing
- Department of Ecology and Conservation Biology, Texas A&M University, College Station, TX 77843, USA
| | - Helena Machado
- Department of Earth Sciences, University of Oregon, Eugene, OR 97403, USA
| | - Samantha M. McCrane
- Department of Anthropology, University of Florida, Gainesville, FL 32611, USA
| | - Bryan McLean
- Department of Biology, University of North Carolina, Greensboro, NC 27412, USA
| | - Michèle E. Morgan
- Peabody Museum of Archaeology and Ethnology, Harvard University, Cambridge, MA 02138, USA
| | - Suzanne Pilaar Birch
- Department of Anthropology, University of Georgia, Athens, GA 30602, USA
- Department of Geography, University of Georgia, Athens, GA 30602, USA
| | - Denne Reed
- Department of Anthropology, University of Texas, Austin, Austin, TX 78712, USA
| | - Elizabeth J. Reitz
- Georgia Museum of Natural History, University of Georgia, Athens, GA 30602, USA
| | - Neeka Sewnath
- Department of Biology, University of Florida, Gainesville, FL 32611, USA
| | - Nathan S. Upham
- School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA
| | - Amelia Villaseñor
- Department of Anthropology, University of Arkansas, Fayetteville, AR 72701, USA
| | - Laurel Yohe
- Department of Bioinformatics and Genomics, University of North Carolina Charlotte, Charlotte, NC 28223, USA
| | - Edward B. Davis
- Department of Earth Sciences, University of Oregon, Eugene, OR 97403, USA
- Department of Biology and Chemistry, Morehead State University, Morehead, KY 40351, USA
- Corresponding author
| | - Robert P. Guralnick
- Florida Museum of Natural History, University of Florida, Gainesville, FL 32611, USA
- Corresponding author
| |
Collapse
|
2
|
LeFebvre MJ, Brenskelle L, Wieczorek J, Kansa SW, Kansa EC, Wallis NJ, King JN, Emery KF, Guralnick R. ZooArchNet: Connecting zooarchaeological specimens to the biodiversity and archaeology data networks. PLoS One 2019; 14:e0215369. [PMID: 30978247 PMCID: PMC6461259 DOI: 10.1371/journal.pone.0215369] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Accepted: 04/01/2019] [Indexed: 11/30/2022] Open
Abstract
Interdisciplinary collaborations and data sharing are essential to addressing the long history of human-environmental interactions underlying the modern biodiversity crisis. Such collaborations are increasingly facilitated by, and dependent upon, sharing open access data from a variety of disciplinary communities and data sources, including those within biology, paleontology, and archaeology. Significant advances in biodiversity open data sharing have focused on neontological and paleontological specimen records, making available over a billion records through the Global Biodiversity Information Facility. But to date, less effort has been placed on the integration of important archaeological sources of biodiversity, such as zooarchaeological specimens. Zooarchaeological specimens are rich with both biological and cultural heritage data documenting nearly all phases of human interaction with animals and the surrounding environment through time, filling a critical gap between paleontological and neontological sources of data within biodiversity networks. Here we describe technical advances for mobilizing zooarchaeological specimen-specific biological and cultural data. In particular, we demonstrate adaptations in the workflow used by biodiversity publisher VertNet to mobilize Darwin Core formatted zooarchaeological data to the GBIF network. We also show how a linked open data approach can be used to connect existing biodiversity publishing mechanisms with archaeoinformatics publishing mechanisms through collaboration with the Open Context platform. Examples of ZooArchNet published datasets are used to show the efficacy of creating this critically needed bridge between biological and archaeological sources of open access data. These technical advances and efforts to support data publication are placed in the larger context of ZooarchNet, a new project meant to build community around new approaches to interconnect zoorchaeological data and knowledge across disciplines.
Collapse
Affiliation(s)
- Michelle J. LeFebvre
- Florida Museum of Natural History, University of Florida, Gainesville, Florida, United States of America
| | - Laura Brenskelle
- Florida Museum of Natural History, University of Florida, Gainesville, Florida, United States of America
| | - John Wieczorek
- Museum of Vertebrate Zoology, University of California, Berkeley, California, United States of America
| | - Sarah Whitcher Kansa
- Open Context, San Francisco, California, United States of America
- Archaeological Research Facility, University of California, Berkeley, California, United States of America
| | - Eric C. Kansa
- Open Context, San Francisco, California, United States of America
| | - Neill J. Wallis
- Florida Museum of Natural History, University of Florida, Gainesville, Florida, United States of America
| | - Jessica N. King
- Florida Museum of Natural History, University of Florida, Gainesville, Florida, United States of America
| | - Kitty F. Emery
- Florida Museum of Natural History, University of Florida, Gainesville, Florida, United States of America
| | - Robert Guralnick
- Florida Museum of Natural History, University of Florida, Gainesville, Florida, United States of America
| |
Collapse
|
3
|
King JN, Christinaz C, Strehlau G, Hornfeld J. Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs. J Vet Pharmacol Ther 2018; 41:485-489. [PMID: 29392741 DOI: 10.1111/jvp.12475] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 11/22/2017] [Indexed: 11/27/2022]
Abstract
To support their combined use, the objective of the study was to evaluate the effects of benazepril and pimobendan on serum angiotensin-converting enzyme (ACE) activity in dogs. A total of 48 healthy beagle dogs were randomized into four groups (n = 12 per group) in a parallel-group design study: A (control, placebo twice daily (BID)); B (0.5-1.0 mg/kg benazepril once daily (SID) in the morning, placebo in the evening); C (0.25-0.5 mg/kg benazepril BID); D (0.25-0.5 mg/kg benazepril and 0.125-0.25 mg/kg pimobendan, both BID). The test items were administered orally for 15 days. Serum ACE activity was measured on days 1 and 15. Groups B, C and D had significantly lower average serum ACE activity compared to baseline and to the control group, on both days 1 and 15. There were no significant differences in average ACE activity between groups B, C and D. Noninferiority of group C to B was demonstrated. In conclusion, 0.25-0.5 mg/kg benazepril administered BID produced noninferior inhibition of serum ACE activity compared to 0.5-1.0 mg/kg benazepril dosed SID. Pimobendan had no significant effect on benazepril's action on serum ACE activity. The results support the use of benazepril BID in dogs and in combination with pimobendan.
Collapse
Affiliation(s)
- J N King
- Companion Animal Development, Elanco Animal Health, Basel, Switzerland
| | - C Christinaz
- Centre de Recherche Santé Animale, Elanco Animal Health, St Aubin, Switzerland
| | - G Strehlau
- Companion Animal Development, Elanco Animal Health, Basel, Switzerland
| | - J Hornfeld
- Centre de Recherche Santé Animale, Elanco Animal Health, St Aubin, Switzerland
| |
Collapse
|
4
|
Friton G, Thompson C, Karadzovska D, King S, King JN. Efficacy and Safety of Injectable Robenacoxib for the Treatment of Pain Associated With Soft Tissue Surgery in Dogs. J Vet Intern Med 2017; 31:832-841. [PMID: 28514527 PMCID: PMC5435044 DOI: 10.1111/jvim.14698] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2016] [Revised: 01/17/2017] [Accepted: 02/23/2017] [Indexed: 12/19/2022] Open
Abstract
Background Nonsteroidal anti‐inflammatory drugs (NSAIDs) are used routinely to control pain and inflammation after surgery in dogs. Robenacoxib is a cyclooxygenase‐2 selective NSAID. Hypothesis/Objective Assess the clinical efficacy and safety of an injectable formulation of robenacoxib in dogs undergoing surgery. Animals Three hundred and seventeen client‐owned dogs (N = 159 robenacoxib or N = 158 placebo). Methods In this prospective, multicenter, randomized, masked, placebo‐controlled, parallel‐group study, dogs received a SC injection of either robenacoxib, at a target dose of 2.0 mg/kg, or placebo once prior to surgery and for 2 additional days postoperatively. Pain assessments were performed using the short form of the Glasgow Composite Measure Pain Scale (CMPS‐SF). The primary efficacy variable was treatment success/failure, with failure defined as the need for rescue therapy to control pain or withdrawal of the dog from the study due to an adverse event. Results Significantly (P = .006) more dogs administered robenacoxib were considered treatment successes (108 of 151, 73.7%) compared to dogs given placebo (85 of 152, 58.1%). Total pain scores (P < .01), pain at the surgery sites (response to touch, P < .01), and posture/activity (P < .05) were significantly improved at 3, 5, and 8 hours postextubation in dogs receiving robenacoxib versus placebo. Conclusions and Clinical Importance Robenacoxib administered by SC injection prior to surgery and for 2 additional days postoperatively was effective and well tolerated in the control of postoperative pain and inflammation associated with soft tissue surgery in dogs.
Collapse
Affiliation(s)
- G Friton
- Companion Animal Development, Elanco Animal Health Inc, Basel, Switzerland
| | - C Thompson
- Companion Animal Development, Elanco Animal Health Inc, Greenfield, IN
| | - D Karadzovska
- Food Animal Development, Elanco Australasia Pty Limited, Kemps Creek, NSW, Australia
| | - S King
- Companion Animal Development, Elanco Animal Health Inc, Greenfield, IN
| | - J N King
- Companion Animal Development, Elanco Animal Health Inc, Basel, Switzerland
| |
Collapse
|
5
|
King JN, Font A, Rousselot JF, Ash RA, Bonfanti U, Brovida C, Crowe ID, Lanore D, Pechereau D, Seewald W, Strehlau G. Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial. J Vet Intern Med 2017; 31:1113-1122. [PMID: 28669137 PMCID: PMC5508345 DOI: 10.1111/jvim.14726] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 02/16/2017] [Accepted: 04/06/2017] [Indexed: 01/10/2023] Open
Abstract
Background Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. Objective To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. Animals Forty‐nine client‐owned dogs with CKD. Methods Dogs were randomized to benazepril (0.25 to <0.5 mg/kg) or placebo once daily for up to 2 years in a prospective, multicenter, blinded clinical trial. The primary endpoint variable was the renal survival time, defined as the time from inclusion in the study to the treatment failure endpoint of death or euthanasia or need for administration of parenteral fluids related to renal failure. Results No benefit of benazepril versus placebo was detected for renal survival time in all dogs; median (95% confidence interval (CI)) survival times were 305 (53–575) days in the benazepril group and 287 (152‐not available) in the placebo group (P = .53). Renal survival times were not significantly longer with benazepril compared to placebo for subgroups: hazard ratios (95% CI) were 0.50 (0.21–1.22) with P = .12 for initial urine protein‐to‐creatinine ratio (UPC) >0.5, and 0.38 (0.12–1.19) with P = .080 for initial UPC >0.5 plus plasma creatinine ≤440 μmol/L. Proteinuria, assessed from the UPC, was significantly (P = .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events. Conclusions and Clinical Relevance Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time.
Collapse
Affiliation(s)
- J N King
- Elanco Animal Health, Basel, Switzerland
| | - A Font
- Hospitar Ars Veterinaria, Barcelona, Spain
| | - J-F Rousselot
- Clinique vétérinaire du Clos des Camélias, Colombes, France
| | - R A Ash
- Grove Lodge Veterinary Group, Brighton, UK
| | - U Bonfanti
- La Vallonèa Veterinary Diagnostic Laboratory, Alessano, Italy
| | - C Brovida
- ANUBI Ospedale per Animali da Compagnia, Moncalieri/Torino, Italy
| | - I D Crowe
- Kingsway Veterinary Group, Skipton, UK
| | - D Lanore
- Clinique Vétérinaire Alliance, Bordeaux, France
| | | | - W Seewald
- Elanco Animal Health, Basel, Switzerland
| | - G Strehlau
- Elanco Animal Health, Basel, Switzerland
| |
Collapse
|
6
|
Kuntz EA, Strehlau G, Giraudel JM, King JN. Safety of a benazepril and pimobendan combination tablet in adult healthy dogs. J Vet Pharmacol Ther 2017. [PMID: 28649790 DOI: 10.1111/jvp.12423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The objective of the study was to investigate the safety of a combination tablet of benazepril and pimobendan, Fortekor PLUS® , in a randomized, blinded, parallel-group design study in healthy adult beagle dogs. The test article, Fortekor PLUS® tablets, was administered orally twice daily for 6 months at one, two, and four times the highest recommended dosage of 0.5 mg/kg benazepril hydrochloride/0.25 mg/kg pimobendan (four males and four females per group). An additional control group was sham-dosed. Fortekor PLUS® did not induce any treatment-related effects on body weight, food consumption, neurological, ophthalmologic or physical assessments over the 6-month treatment period. The test article was possibly associated with an increased frequency of occasional vomiting. Fortekor PLUS® was associated with small, but significant, increases in heart rate and reductions in PR and QT intervals, which were assessed by electrocardiography. These effects were most probably related to reflex tachycardia secondary to reduced systemic blood pressure. Statistically significant changes in some clinical pathology variables were noted after test article administration, but were considered to be of no clinical relevance as values remained within reference ranges and/or were not dose-dependent. No treatment-related macroscopic or microscopic findings were observed. In conclusion, Fortekor PLUS® tablets were well tolerated in healthy adult dogs when administered at one, two, and four times the highest recommended dosage for 6 months.
Collapse
Affiliation(s)
- E A Kuntz
- Elanco Animal Health, Companion Animal Development, Basel, Switzerland
| | - G Strehlau
- Elanco Animal Health, Companion Animal Development, Basel, Switzerland
| | - J M Giraudel
- Elanco Animal Health, Companion Animal Development, Basel, Switzerland
| | - J N King
- Elanco Animal Health, Companion Animal Development, Basel, Switzerland
| |
Collapse
|
7
|
Desevaux C, Marotte-Weyn AA, Champeroux P, King JN. Evaluation of cardiovascular effects of intravenous robenacoxib in dogs. J Vet Pharmacol Ther 2017; 40:e62-e64. [PMID: 28457010 DOI: 10.1111/jvp.12411] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 03/22/2017] [Indexed: 11/27/2022]
Abstract
The objective of the study was to assess the cardiovascular effects of intravenous (IV) dosing with robenacoxib (Onsior® ) in conscious adult healthy beagle dogs. The study employed a randomized, open, placebo-controlled, four-phase Latin square design. A total of eight dogs received a single dose of 2 mg/kg and 4 mg/kg IV robenacoxib (test groups), 2 mg/kg subcutaneous (SC) robenacoxib (reference dose and route), and IV isotonic saline (control). There were no significant differences between groups for clinical observations, buccal mucosal bleeding time or blood hematology, coagulation, and clinical chemistry variables in all eight dogs. In a subset of four dogs, no significant differences between groups were detected using telemetric assessment for arterial blood pressure, heart rate, electrocardiogram, or body temperature over 8 hr postdose. In conclusion, no significant cardiovascular effects were detected after a single IV dose of 2 or 4 mg/kg robenacoxib in conscious healthy dogs.
Collapse
Affiliation(s)
- C Desevaux
- Safety, Elanco Animal Health, Basel, Switzerland
| | | | | | - J N King
- Companion Animal Development, Elanco Animal Health, Basel, Switzerland
| |
Collapse
|
8
|
Pelligand L, Soubret A, King JN, Elliott J, Mochel JP. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats. CPT Pharmacometrics Syst Pharmacol 2016; 5:625-635. [PMID: 27770596 PMCID: PMC5193001 DOI: 10.1002/psp4.12141] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 09/19/2016] [Indexed: 11/11/2022] Open
Abstract
The objective of this study was to model the pharmacokinetics (PKs) of robenacoxib in cats using a nonlinear mixed-effects (NLME) approach, leveraging all available information collected from cats receiving robenacoxib s.c. and/or i.v.: 47 densely sampled laboratory cats and 36 clinical cats sparsely sampled preoperatively. Data from both routes were modeled sequentially using Monolix 4.3.2. Influence of parameter correlations and available covariates (age, gender, bodyweight, and anesthesia) on population parameter estimates were evaluated by using multiple samples from the posterior distribution of the random effects. A bicompartmental disposition model with simultaneous zero and first-order absorption best described robenacoxib PKs in blood. Clearance was 0.502 L/kg/h and the bioavailability was high (78%). The absorption constant point estimate (Ka = 0.68 h-1 ) was lower than beta (median, 1.08 h-1 ), unveiling flip-flop kinetics. No dosing adjustment based on available covariates information is advocated. This modeling work constitutes the first application of NLME in a large feline population.
Collapse
Affiliation(s)
- L Pelligand
- Royal Veterinary CollegeHatfieldUnited Kingdom
| | - A Soubret
- Department of PharmacometricsNovartis PharmaceuticalsBaselSwitzerland
| | - JN King
- Elanco Animal Health Inc.BaselSwitzerland
| | - J Elliott
- Royal Veterinary CollegeHatfieldUnited Kingdom
| | - JP Mochel
- Department of PharmacometricsNovartis PharmaceuticalsBaselSwitzerland
| |
Collapse
|
9
|
Panteri A, Kukk A, Desevaux C, Seewald W, King JN. Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs. J Vet Pharmacol Ther 2016; 40:44-56. [PMID: 27302598 DOI: 10.1111/jvp.12325] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Accepted: 04/20/2016] [Indexed: 11/30/2022]
Abstract
Combined use of angiotensin-converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs may induce acute kidney injury, especially when combined with diuretics. The objective of this investigation was to evaluate the effect of benazepril, robenacoxib and their combination in healthy dogs. In each of two studies (studies 1 and 2), 32 beagle dogs were randomized into one of four groups in a parallel-group design. Groups received once-daily oral treatment for 7 days with placebo, benazepril, robenacoxib or benazepril plus robenacoxib. In study 2, all dogs received additionally 2 mg/kg furosemide orally twice daily. The primary endpoint was the glomerular filtration rate (GFR) estimated from the plasma clearance of iohexol. Secondary endpoints included standard clinical monitoring and, in study 2, plasma renin activity, urine volume, specific gravity and aldosterone concentration and water intake. Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system. Benazepril and robenacoxib, administered alone or in combination, were tolerated well, did not decrease GFR with or without co-administration of furosemide and significantly reduced urinary aldosterone concentrations. No increased risk of acute kidney injury was identified with the combination of benazepril and robenacoxib in healthy dogs. Different effects might occur in dogs with heart or renal disease.
Collapse
Affiliation(s)
- A Panteri
- Preclinical, Elanco Centre de Recherche Santé Animale, St-Aubin, Switzerland
| | - A Kukk
- Preclinical, Elanco Centre de Recherche Santé Animale, St-Aubin, Switzerland
| | - C Desevaux
- Safety, Elanco Animal Health, Basel, Switzerland
| | - W Seewald
- Companion Animal Development, Elanco Animal Health, Basel, Switzerland
| | - J N King
- Companion Animal Development, Elanco Animal Health, Basel, Switzerland
| |
Collapse
|
10
|
Pelligand L, Suemanotham N, King JN, Seewald W, Syme H, Smith K, Lees P, Elliott J. Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney. BMC Vet Res 2015; 11:296. [PMID: 26634699 PMCID: PMC4669647 DOI: 10.1186/s12917-015-0598-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Accepted: 11/18/2015] [Indexed: 11/21/2022] Open
Abstract
Background The role of cyclooxygenase(COX)-1 and COX-2 in the saluretic and renin-angiotensin responses to loop diuretics in the cat is unknown. We propose in vivo characterisation of isoform roles in a furosemide model by administering non-steroidal anti-inflammatory drugs (NSAIDs) with differing selectivity profiles: robenacoxib (COX-2 selective) and ketoprofen (COX-1 selective). Results In this four period crossover study, we compared the effect of four treatments: placebo, robenacoxib once or twice daily and ketoprofen once daily concomitantly with furosemide in seven healthy cats. For each period, urine and blood samples were collected at baseline and within 48 h of treatment starting. Plasma renin activity (PRA), plasma and urinary aldosterone concentrations, glomerular filtration rate (GFR) and 24 h urinary volumes, electrolytes and eicosanoids (PGE2, 6-keto-PGF1α, TxB2), renal injury biomarker excretions [N-acetyl-beta-D-glucosaminidase (NAG) and Gamma-Glutamyltransferase] were measured. Urine volume (24 h) and urinary sodium, chloride and calcium excretions increased from baseline with all treatments. Plasma creatinine increased with all treatments except placebo, whereas GFR was significantly decreased from baseline only with ketoprofen. PRA increased significantly with placebo and once daily robenacoxib and the increase was significantly higher with placebo compared to ketoprofen (10.5 ± 4.4 vs 4.9 ± 5.0 ng ml−1 h−1). Urinary aldosterone excretion increased with all treatments but this increase was inhibited by 75 % with ketoprofen and 65 % with once daily robenacoxib compared to placebo. Urinary PGE2 excretion decreased with all treatments and excretion was significantly lower with ketoprofen compared to placebo. Urinary TxB2 excretion was significantly increased from baseline only with placebo. NAG increased from baseline with all treatments. Immunohistochemistry on post-mortem renal specimens, obtained from a different group of cats that died naturally of non-renal causes, suggested constitutive COX-1 and COX-2 co-localization in many renal structures including the macula densa (MD). Conclusions These data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin secreting cells in cats exposed to furosemide. Co-localization of COX isoenzymes in MD cells supports the functional data reported here. Electronic supplementary material The online version of this article (doi:10.1186/s12917-015-0598-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- L Pelligand
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK. .,Department of Clinical Sciences and Services, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, AL9 7TA, Hertfordshire, UK.
| | - N Suemanotham
- Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
| | - J N King
- Novartis Animal Health Inc., Clinical Development, Basel, Switzerland.
| | - W Seewald
- Novartis Animal Health Inc., Clinical Development, Basel, Switzerland.
| | - H Syme
- Department of Clinical Sciences and Services, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, AL9 7TA, Hertfordshire, UK.
| | - K Smith
- Department of Pathology and Pathogen Biology, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, AL9 7TA, Hertfordshire, UK.
| | - P Lees
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK.
| | - J Elliott
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK.
| |
Collapse
|
11
|
King JN, Rudaz C, Borer L, Jung M, Seewald W, Lees P. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Res Vet Sci 2009; 88:497-506. [PMID: 20004922 DOI: 10.1016/j.rvsc.2009.11.002] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2008] [Revised: 06/24/2009] [Accepted: 11/04/2009] [Indexed: 02/02/2023]
Abstract
In vitro whole blood canine assays were used to quantify the inhibitory actions of the novel non-steroidal anti-inflammatory drug (NSAID) robenacoxib on the cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, in comparison with other drugs of the NSAID class. COX-1 activity was determined by measuring serum thromboxane (Tx)B(2) synthesis in blood samples allowed to clot at 37 degrees C for 1h. COX-2 activity was determined by measuring prostaglandin (PG)E(2) synthesis in blood samples incubated at 37 degrees C for 24h in the presence of lipopolysaccharide. The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88). Selectivity expressed as the clinically relevant ratio IC(20) COX-1:IC(80) COX-2 was highest for robenacoxib (19.8) compared to deracoxib (2.3), S+ carprofen (2.5), R- carprofen (2.1), nimesulide (1.8), etodolac (0.76), meloxicam (0.46) and ketoprofen (0.21). An in vivo pharmacokinetic ex vivo pharmacodynamic study in the dog established dosage and concentration-effect relationships for single oral doses of robenacoxib over the dosage range 0.5-8.0mg/kg. Values of C(max) and AUC were linearly related to dosage over the tested range. Robenacoxib did not inhibit serum TxB(2) synthesis (COX-1) ex vivo at dosages of 0.5-4.0mg/kg and produced only transient inhibition (at the 1h and 2h sampling times) at the 8mg/kg dosage. All dosages of robenacoxib (0.5-8mg/kg) produced marked, significant and dose related inhibition of PGE(2) synthesis (COX-2) ex vivo. The data demonstrate that in the dog robenacoxib is a highly selective inhibitor of the COX-2 isoform of COX, and significantly inhibits COX-2 and spares COX-1 in vivo when administered orally over the dosage range 0.5-4.0mg/kg.
Collapse
Affiliation(s)
- J N King
- Novartis Animal Health Inc., CH-4058, Basel, Switzerland.
| | | | | | | | | | | |
Collapse
|
12
|
Giraudel JM, King JN, Jeunesse EC, Lees P, Toutain PL. Use of a pharmacokinetic/pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib. J Vet Pharmacol Ther 2009; 32:18-30. [PMID: 19161452 DOI: 10.1111/j.1365-2885.2008.01016.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This study investigated the analgesic, anti-inflammatory and antipyretic efficacy of the new COX-2 selective inhibitor robenacoxib in the cat and established pharmacodynamic (PD) parameters for these effects. Robenacoxib, at a dosage of 2 mg/kg administered subcutaneously, was evaluated in a kaolin-induced paw inflammation model in 10 cats, using both clinically relevant endpoints (lameness scoring, locomotion tests) and other indicators of inflammation (body and skin temperature, thermal pain threshold) to establish its pharmacological profile. A pharmacokinetic/pharmacodynamic (PK/PD) modelling approach, based on indirect response models, was used to describe the time course and magnitude of the responses to robenacoxib. All endpoints demonstrated good responsiveness to robenacoxib administration and both the magnitude and time courses of responses were well described by the indirect pharmacodynamic response models. Pharmacokinetic and clinically relevant pharmacodynamic parameters were used to simulate dosage regimens that will assist the planning of clinical trials and the selection of an optimal dosage regimen for robenacoxib in the cat.
Collapse
Affiliation(s)
- J M Giraudel
- Ecole Nationale Vétérinaire de Toulouse, UMR 181 Physiopathologie et Toxicologie Expérimentales INRA, ENVT, Toulouse Cedex, France
| | | | | | | | | |
Collapse
|
13
|
Abstract
Robenacoxib is a new nonsteroidal anti-inflammatory drug (NSAID) developed for use in companion animal medicine. The objectives of this study were: to quantify the inhibitory actions of robenacoxib on cyclooxygenase (COX) isoenzymes in feline whole blood assays; to establish blood concentration-time profiles of robenacoxib after intravenous and subcutaneous dosing in the cat and; to predict the time courses of inhibition of COX isoforms by robenacoxib. COX-1 and COX-2 activities in heparinized feline whole blood samples were induced with calcium ionophore and lipopolysaccharide, respectively. Inhibition of thromboxane B2 provided a marker of both COX-1 and COX-2 activities and a nonlinear parametric mixed effects modelling approach was used to establish the pharmacodynamic parameters describing this inhibition. Mean values (and prediction intervals) of IC50 were 28.9 (16.4-51.1) microM (COX-1) and 0.058 (0.010-0.340) microM (COX-2). These parameters were used to compute several selectivity indices. Selectivity IC ratios (COX-1:COX-2) were 502.3 (IC50/IC50), 451.6 (IC95/IC95) and 17.05 (IC20/IC80). Based on a clinically recommended dosage regimen of 2 mg/kg, it was predicted that the corresponding mean robenacoxib blood concentration over the first 12 h after drug administration corresponded to 5% inhibition of COX-1 and 90% inhibition of COX-2.
Collapse
Affiliation(s)
- J M Giraudel
- Department of Veterinary Basic Sciences, Royal Veterinary College, Hertfordshire, UK
| | | | | | | |
Collapse
|
14
|
Abstract
An analytical method was developed and validated for the measurement of the novel analgesic and anti-inflammatory drug robenacoxib in blood and plasma of dogs and cats. To prevent nonreproducible carry-over effects, an initial solid phase extraction procedure was followed by high pressure liquid chromatography analysis for samples with concentrations in the range 500 to 20,000 ng/mL. To improve accuracy, samples of concentration 3 to 100 ng/mL were analyzed by liquid chromatography-mass spectrometry. Applying these methods, blood concentration-time profiles and pharmacokinetic variables of robenacoxib in dogs were determined in a four-phase cross-over study, which compared different routes of administration of the drug, including intravenous (i.v.) injection, oral application with and without feed, and subcutaneous (s.c.) application. After i.v. administration the mean clearance from blood was 0.81 L/kg/h, the volume of distribution was 0.77 L/kg for the elimination phase and 0.24 L/kg for steady-state, and the terminal half-life in blood was 0.63 h. Maximum blood concentrations were obtained in less than 1 h following oral or s.c. application. Absolute bioavailability was 88% after s.c. injection, 84% after oral administration to fasted dogs, but was reduced to 62% when applied orally to fed dogs. In canine and feline plasma the degree of binding of robenacoxib to plasma protein in vitro was greater than 98%. The blood:plasma concentration ratio was 0.44:1 in the dog and 0.65:1 in the cat. In conclusion analytical methods for the quantification of robenacoxib in blood and plasma in the dog and cat were developed and validated. In dogs, robenacoxib has good bioavailability after oral (84%) and subcutaneous (88%) administration.
Collapse
Affiliation(s)
- M Jung
- Novartis Animal Health Research Centre, St-Aubin, Switzerland
| | | | | | | |
Collapse
|
15
|
Abstract
Angiotensin-converting enzyme (ACE) inhibitors represent one of the most commonly used categories of drugs in canine and feline medicine. ACE inhibitors currently approved for use in veterinary medicine are benazepril, enalapril, imidapril and ramipril. They are all pro-drugs administered by oral route. A physiologically based model taking into account the saturable binding to ACE has been developed for pharmacokinetic analysis. The bioavailability of the active compounds from their respective pro-drug is low. The active metabolites are eliminated by renal, hepatorenal or biliary excretion, according to the drug. The elimination half-life of the free fraction of the active compounds is very short (ranging from approximately 10 min to 2 h). ACE inhibitors are generally well tolerated. Benazepril, enalapril, imidapril and ramipril are approved for dogs with chronic heart failure (CHF). The efficacy of ACE inhibitors has been convincingly demonstrated in dogs with CHF, especially in those with chronic valvular disease. In such clinical settings, ACE inhibitors improve hemodynamics and clinical signs, and increase survival time. In cats with cardiovascular disease, little information is available except for reports of some benefit in cats with hypertrophic cardiomyopathy in two non-controlled investigations. ACE inhibitors have also a mild to moderate hypotensive effect. There is also evidence to recommend ACE inhibitors in dogs and cats with chronic renal failure (CRF). They decrease the glomerular capillary pressure, have antiproteinuric effects, tend to delay the progression of CRF and to limit the extent of renal lesions.
Collapse
Affiliation(s)
- H P Lefebvre
- UMR 181 INRA-ENVT Physiopathologie et Toxicologie Expérimentales, National Veterinary School, Toulouse cedex 03, France.
| | | | | | | | | | | |
Collapse
|
16
|
Affiliation(s)
- J N King
- Novartis Animal Health Inc., Basel, Switzerland.
| | | | | | | |
Collapse
|
17
|
Abstract
The disposition and effect of benazepril and its active metabolite, benazeprilat, were evaluated in cats using a pharmacokinetic/pharmacodynamic model. Cats received single 1 mg/kg doses of intravenous 14C-benazeprilat and oral 14C-benazepril.HCl, and single and repeat (eight daily) oral administrations of 0.25, 0.5 and 1.0 mg/kg nonlabelled benazepril.HCl. The pharmacokinetic endpoints were plasma concentrations of benazepril and benazeprilat, and recovery of radioactivity in faeces and urine. The pharmacodynamic endpoint was plasma angiotensin-converting enzyme (ACE) activity. Benazeprilat data were fitted to an equation corresponding to a single-compartment model with a volume equal to the blood space (Vc = 0.093 L/kg). Within this space, benazeprilat was bound nonlinearly to ACE, which was mainly tissular (89.4%) rather than circulating (10.6%). Free benazeprilat was eliminated quickly from the central compartment (t1/2 approximately 1.0 h; Cl approximately 0.125 L/kg/h), elimination being principally biliary ( approximately 85%) rather than urinary ( approximately 15%). Nevertheless, inhibition of ACE was long-lasting (t1/2 16-23 h) due to high affinity binding of benazeprilat to ACE (Kd approximately 3.5 mmol/L, IC50 approximately 4.3 mmol/L). Simulations using the model predict a lack of proportionality between dose of benazepril, plasma benazeprilat concentrations and effect due to the nonlinear binding of benazeprilat to ACE. For example, increasing the dose of benazepril (e.g. above 0.125 mg/kg q24 h) produced only small incremental inhibition of ACE (either peak effect or duration of action).
Collapse
Affiliation(s)
- J N King
- Novartis Animal Health Inc., CH-4002, Basel, Switzerland.
| | | | | |
Collapse
|
18
|
|
19
|
Abstract
The effect of renal insufficiency was studied on the pharmacokinetics (PK) and pharmacodynamics (PD) of the angiotensin-converting enzyme (ACE) inhibitor benazepril in cats. The active metabolite of benazepril, benazeprilat, is eliminated principally ( approximately 85%) via biliary excretion in cats. A total of 20 control animals and 32 cats with moderate renal insufficiency induced by partial nephrectomy were used. Assessments were made at steady state after treatment with placebo or benazepril (0.25-2 mg/kg) once daily for a minimum of 10 days. The PK endpoint was the AUC (0-->24 h) of total plasma benazeprilat. The PD endpoints were systolic, diastolic and mean blood pressures (respectively SBP, DBP and MBP) measured by telemetry, and plasma ACE activity, assessed by an ex vivo assay. Renal function was assessed by glomerular filtration rate (GFR), measured by inulin clearance, and plasma creatinine concentrations (1/PCr). As compared with control animals, the renal insufficient cats had a 78% reduction in GFR (0.57 +/- 0.41 mL/min kg), increased plasma creatinine (2.7 +/- 1.0 mg/dL), urea (44.0 +/- 11.9 mg/dL) and ACE activity, and moderately increased blood pressure (SBP 171.8 +/- 5.1 mmHg) (all parameters P < 0.05). Renal insufficient cats receiving benazepril had significantly (P < 0.05) lower SBP, DBP, MBP and ACE, and higher GFR values as compared with placebo-treated animals. There were no significant differences in SBP, DBP, MBP, benazeprilat or ACE values according to the degree of renal insufficiency in cats receiving benazepril. It is concluded that no dose adjustment of benazepril is necessary in cats with moderate renal insufficiency.
Collapse
Affiliation(s)
- J N King
- Novartis Animal Health Inc., Basel, Switzerland.
| | | | | | | |
Collapse
|
20
|
Abstract
OBJECTIVE To determine the effects of clomipramine hydrochloride on heart rate and rhythm in dogs. ANIMALS 17 healthy Beagles. PROCEDURES In experiment 1, 8 dogs received placebo or clomipramine (20 mg/kg of body weight, q 24 h, PO) for 7 days in a 2-way crossover design. In experiment 2, 9 dogs were evaluated for 48 hours before and 24 hours after oral administration of clomipramine (4 or 12 mg/kg) in a 2-way crossover design. Electrocardiogram and heart rate were monitored continuously by use of telemetry. RESULTS A significant diurnal rhythm in heart rate was detected; minimum values were recorded at night. Administration of 20 mg of clomipramine/kg induced a significant reduction in heart rate, with peak effect achieved approximately 12 hours after dosing. Administration of 4 or 12 mg of clomipramine/kg did not result in significant changes in heart rate. Sinoatrial and second-degree atrioventricular block and ventricular escape beats were observed during periods of slow heart rate in more dogs that received clomipramine (3 to 4 of 8 dogs), compared with dogs that received placebo (1 to 2 of 8 dogs), but this difference was not significant. CONCLUSIONS AND CLINICAL RELEVANCE Short-term administration of clomipramine induced benign cardiovascular effects in dogs rather than the potentially dangerous arrhythmias or tachycardia reported following administration of tricyclic antidepressants to humans. Precautions regarding cardiovascular effects may not be needed for the use of clomipramine in healthy dogs.
Collapse
Affiliation(s)
- J L Pouchelon
- Department of Clinical Veterinary Medicine, University of Maisons-Alfort, France
| | | | | | | | | |
Collapse
|
21
|
Toutain PL, Lefebvre HP, King JN. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. J Pharmacol Exp Ther 2000; 292:1087-93. [PMID: 10688627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
The pharmacokinetic disposition of benazeprilat, an angiotensin-converting enzyme (ACE) inhibitor (ACEI), was assessed with a nonlinear binding model in dogs. A single oral benazepril dose, a single i.v. benazeprilat dose, or a daily oral dose of benazepril for 14 consecutive days was administered. The activity of benazeprilat was assessed by measuring plasma ACE inhibition with an ex vivo assay. Benazeprilat data were fitted to equations corresponding to a monocompartmental model with a volume equal to the extracellular space ( approximately 0.2 l/kg) in which a fraction of benazeprilat was nonlinearily bound to ACE with both a saturable tissue and nontissue binding. The half-life of benazeprilat elimination determined from this physiologically based model was 39 +/- 6 min. The estimated maximal binding capacity of benazeprilat to ACE was approximately 23.5 nmol/kg, 90% of which was tissular. The estimated equilibrium constant of dissociation (K(d)) of benazeprilat to ACE was 2.7 to 4.5 nM. IC(50) values were one order of magnitude lower than K(d) values (i.e., approximately 0.27 nM). The nonlinear disposition of benazeprilat raised several issues and it was concluded that the benazeprilat concentration profile was only relevant to definition of an optimal dosage regimen if the appropriate kinetic model was used to interpret the plasma data.
Collapse
Affiliation(s)
- P L Toutain
- Ecole Nationale Vétérinaire de Toulouse, et Institut National de la Recherche Agronomique, Unité Associée de Physiopathologie et Toxicologie Expérimentales, Toulouse, France.
| | | | | |
Collapse
|
22
|
Abstract
OBJECTIVE To determine pharmacokinetics of clomipramine and its principle metabolite (desmethylclomipramine) in the plasma of dogs after IV or oral administration of a single dose. ANIMALS 6 male and 6 female Beagles. PROCEDURES Clomipramine was administered IV (2 mg/kg), PO (4 mg/kg) after food was withheld for 15 hours, and PO (4 mg/kg) within 25 minutes after dogs were fed. Plasma clomipramine and desmethylclomipramine concentrations were measured by use of a gas chromatography with mass-selection method. RESULTS Time to peak plasma concentrations of clomipramine and desmethylclomipramine following oral administration was 1.2 hours. For clomipramine, after IV administration, elimination half-life was 5 hours, mean residence time was 3 hours, and plasma clearance was 1.4 L/h/kg. Values for mean residence time and terminal half-life following oral administration were similar to values obtained following IV administration, and systemic bioavailability was approximately 20% for clomipramine and 140% for desmethylclomipramine, indicating fast absorption of clomipramine from the gastrointestinal tract and extensive first-pass metabolism. Administration of clomipramine with food did not alter the area under the concentration versus time curve for desmethylclomipramine but resulted in a 25% increase for clomipramine. Clomipramine and desmethylclomipramine were extensively bound (> 96%) to serum proteins. There were no significant differences in area under the concentration versus time curve between male and female dogs. CONCLUSIONS AND CLINICAL RELEVANCE Results indicate that there should not be any clinically important differences in efficacy regardless of whether clomipramine is administered with or without food.
Collapse
Affiliation(s)
- J N King
- Novartis Animal Health, Werk Rosenthal, Basel, Switzerland
| | | | | | | |
Collapse
|
23
|
Abstract
OBJECTIVE To determine pharmacokinetics of clomipramine and its principle metabolite (desmethylclomipramine) in the plasma of dogs following single-dose and repeated-dose oral administration at various dosages. ANIMALS 9 male and 9 female Beagles. PROCEDURES Clomipramine was administered orally at a dose of 1, 2, or 4 mg/kg to 3 male and 3 female dogs, first as a single dose and then, after an interval of 14 days, twice daily for 10 days. Plasma clomipramine and desmethylclomipramine concentrations were measured by use of a gas chromatography with mass-selection method. RESULTS Dose-related accumulation was detected following repeated-dose administration. Accumulation ratios after administration of clomipramine at dosages of 1, 2, and 4 mg/kg twice daily were 1.4, 1.6, and 3.8, respectively, for clomipramine and 2.1, 3.7, and 7.6, respectively, for desmethylclomipramine. Terminal half-life increased slightly (1.6-fold for clomipramine and 1.2-fold for desmethylclomipramine) with repeated-dose administration but remained short in all groups (< or = 4 hours). Steady state was reached within 4 days in all animals. Ratios of the areas under the concentration versus time curves from time 0 to 12 hours for clomipramine and desmethylclomipramine were 3.9, 3.1, and 1.5 after repeated administration at dosages of 1, 2, and 4 mg/kg every 12 hours, respectively. Areas under the concentration versus time curve, mean residence times, and terminal half-lives were not significantly different between male and female dogs. CONCLUSIONS AND CLINICAL RELEVANCE Repeated administration of clomipramine results in higher concentrations of clomipramine than desmethylclomipramine in dogs.
Collapse
Affiliation(s)
- J N King
- Novartis Animal Health, Werk Rosenthal, Basel, Switzerland
| | | | | | | |
Collapse
|
24
|
King JN, Humbert-Droz E, Maurer M. Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril.HCl. J Vet Pharmacol Ther 1999; 22:360-7. [PMID: 10651464 DOI: 10.1046/j.1365-2885.1999.00230.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The plasma pharmacokinetics of benazepril and its active metabolite, benazeprilat, were determined in cats after oral administration of benazepril.HCl at dosages of 0.25, 0.5 and 1.0 mg/kg as a single dose (n = 5 per group) and after once daily application for 8 days (n = 6 per group). Pharmacodynamics were assessed by measurement of plasma angiotensin converting enzyme (ACE) activity. After single administration of benazepril.HCl, maximum benazepril concentrations were recorded at the first sample (2 h) and declined relatively rapidly with an elimination half life (t1/2) of 1.4 h. Highest benazeprilat concentrations were recorded at the first sample (2 h) in most cats and declined biphasically with half lives of each phase of 2.4 and 27.7 h. With repeated administration, plasma benazeprilat concentrations accumulated slightly with accumulation ratios (R) of 1.46, 1.36 and 1.24 for the 0.25, 0.5 and 1.0 mg/kg dosages of benazepril.HCl, respectively (median value of 1.36 for all dosages). All three dosages of benazepril.HCl caused marked inhibition of plasma ACE activity in all cats. The maximum effect (Emax, % inhibition of ACE as compared to baseline) was > or = 98% after single and 100% with repeated administration. The duration of action of benazepril.HCl was long, with > 87% (single) and > 90% (repeat) inhibition of plasma ACE persisting 24 h after dosing. Benazepril.HCl was well tolerated in all animals. Dosages of 0.25-1.0 mg/kg benazepril.HCl once daily are recommended for clinical testing in cats.
Collapse
Affiliation(s)
- J N King
- Novartis Animal Health Inc., Basel, Switzerland
| | | | | |
Collapse
|
25
|
King JN, Maurer M, Morrison CA, Mauron C, Kaiser G. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. Xenobiotica 1997; 27:819-29. [PMID: 9293618 DOI: 10.1080/004982597240181] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
1. The pharmacokinetics of the angiotensin-converting-enzyme (ACE) inhibitor benazepril were evaluated in eight healthy Beagle dogs. Benazepril was administered orally at a dosage of 7.5 mg (about 0.5 mg/kg) both as a single dose and then once daily for 14 consecutive days. The prodrug, benazepril, and its active metabolite, benazeprilat, were measured in plasma using a gas chromatography mass-spectrometry method with mass-selective detection. 2. Benazepril appeared quickly in the plasma (tmax 0.5 h) and was rapidly eliminated by metabolism to benazeprilat. Peak benazeprilat concentrations were attained later (tmax 1.25 h) and declined biphasically with a rapid elimination phase (t1/2 lambda 1 1.1 and 1.7 h after single and the last repeated dose respectively) followed by a terminal elimination phase (t1/2 lambda z 11.7 and 19.0 h after single and repeated dose respectively). The mean residence time for benazeprilat was 15.2 h after the single dose and 17.4 h after the 14th dose. 3. Repeated administration of benazepril produced moderate bioaccumulation of benazeprilat; the ratio of AUC[0-->24 h]'s after the 14th dose as compared with the single dose was 1.47, equivalent to a half-life for accumulation (t1/2acc) of 14.6 h. Steady-state benazeprilat concentrations at peak (Cmax) and trough (Cmin) were reached within three doses. 4. The pharmacodynamics of benazepril were assessed by measurement of plasma ACE activity. After both single doses and at steady-state, benazepril produced inhibition of ACE activity in all dogs that was maximal at peak effect (Emax = 100%) and long-lasting (> 85% inhibition was present at 24 h). The long duration of action of benazepril on plasma ACE is due to the presence of the terminal elimination phase of benazeprilat, even though most of the metabolite is rapidly eliminated from the plasma.
Collapse
Affiliation(s)
- J N King
- NOVARTIS Animal Health, Basel, Switzerland
| | | | | | | | | |
Collapse
|
26
|
King JN, Mauron C, Kaiser G. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. Am J Vet Res 1995; 56:1620-8. [PMID: 8599524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Plasma pharmacokinetic variables of benazeprilat, the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor benazepril, were evaluated in healthy Beagles. Benazeprilat was administered IV at a dosage of 0.5 mg/kg of body weight (n = 9). The elimination of half-life of benazeprilat was 3.5 hours, although an additional terminal phase was observed in some dogs. Vehicle (gelatin capsules) or benazepril at dosages of 0.125, 0.25, 0.5, or 1.0 mg/kg was administered orally as a single administration, then once daily for 15 consecutive days (n = 5 or 6/group). Peak benazeprilat concentrations were rapidly attained by 2 hours. Benazeprilat concentrations accumulated moderately with repeated administration, with a peak concentration that was 23% higher and an area under the concentration-time curve that was 34% higher after the 15th dose of benazepril, compared with values after a single dose. The effective half-life for accumulation for all 4 dosages was 12 hours. Steady-state concentrations at 2 hours after administration were achieved after a median (range) of 1 (1 to 6) dose(s). Pharmacodynamic variables were assessed by measurements of plasma ACE activity after oral administration of benazepril or vehicle. All dosages of benazepril caused profound inhibition of ACE, with rapid onset of activity (time to peak effect, 2 hours) and long duration of action (single administration of all 4 doses induced inhibition of ACE that was significantly different from the value in the control [vehicle-treated] dogs for all time points between 1 and 30 hours). Maximal inhibition at all time points was induced by the 0.25-mg/kg dosage at a single administration and with the lowest dosage tested (0.125 mg/kg) at steady state. At steady state, the 0.25-mg/kg dosage caused (mean +/- SEM) 96.9 +/- 2.0% inhibition of ACE activity at maximal effect and 83.6 +/- 4.2% at trough effect (24 hours after dosing), indicating minimal variation in peak/trough effect. Steady-state inhibition of ACE activity at both peak and trough drug effect was achieved after 1 to 4 doses. The data indicate that benazepril is a potent and long-acting ACE inhibitor in dogs.
Collapse
Affiliation(s)
- J N King
- CIBA Animal Health, Centre de Recherches Agricoles, St Aubin, Switzerland
| | | | | |
Collapse
|
27
|
King JN, Mauron C, Voirol MJ, Le Goff C, Hauffe SA. High performance liquid chromatography and pharmacokinetics of the non-steroidal anti-inflammatory drug oxindanac in calves. J Vet Pharmacol Ther 1994; 17:186-92. [PMID: 7933056 DOI: 10.1111/j.1365-2885.1994.tb00232.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A high-performance liquid chromatographic method for the determination of the non-steroidal anti-inflammatory drug, oxindanac, in calf plasma is described. Recoveries over the concentration range 0.375 to 62.5 micrograms/ml were 90.2-107.8% with interassay coefficients of variation of 2.1-22.3%. The limit of detection was estimated as 0.10 micrograms/ml and the limit of quantification calculated to be 0.24 micrograms/ml in a 1 ml plasma sample. This method was used to establish the pharmacokinetics following intravenous (i.v.), intramuscular (i.m.) and oral (p.o.) administration to calves of oxindanac at a dose rate of 2 mg/kg. The elimination t1/2 was long (t1/2 21.2 h after i.v. injection) and absorption was rapid (t1/2a 0.072 h) and complete (F > 100%) following i.m. administration. Bioavailability was incomplete (F = 66.6%) following p.o. administration to calves that had been fed on milk, and Wagner-Nelson analysis revealed two absorption phases (t1/2's 0.20 and 1.9 h). Oxindanac produced long-lasting inhibition of serum TxB2 production, with mean Emax values (% inhibition) of 96.8, 94.1 and 81.3 following i.v., i.m. and p.o. administration, respectively. A single i.v. or i.m. injection of 2 mg/kg oxindanac will probably be active in calves for at least 36-48 h.
Collapse
Affiliation(s)
- J N King
- CIBA-GEIGY Animal Health, Centre de Recherches Agricoles, St. Aubin, Switzerland
| | | | | | | | | |
Collapse
|
28
|
Abstract
The pharmacokinetics and pharmacodynamics of the non-steroidal antiinflammatory drug, oxindanac, were assessed simultaneously in calves after intravenous (i.v.) administration at dose rates of 0.5, 1, 2, 4 and 8 mg/kg. Plasma pharmacokinetic data were fitted to either two or three compartment open models. The elimination t1/2 was constant in the dose range 0.5 to 4 mg/kg (20.2-22.8 h) and shorter at 8 mg/kg (14.7 h). The pharmacodynamics of oxindanac were assessed by its inhibition of serum TxB2, an index of platelet cyclo-oxygenase activity. Plots of total plasma oxindanac concentration vs. inhibition of serum TxB2 fitted in all cases a sigmoidal Emax equation. There were no significant differences in the estimates for ED50 (1.6-1.9 micrograms/ml), Hill constant (1.3-2.7) or Emax between the doses used in the in vivo studies or when blood was spiked with oxindanac in vitro. Plots of inhibition of serum TxB2 vs. time were prepared from the pharmacokinetic model equations in each calf in combination with a single sigmoidal Emax plot generated in vitro. These data were not significantly different from the results produced in vivo. It is concluded that oxindanac causes reversible inhibition of platelet cyclo-oxygenase in calves. Its inhibition of serum TxB2 can be predicted from total plasma drug concentration, as described by a multicompartmental model, and sigmoidal Emax enzyme kinetics. It was not necessary to take into account factors such as drug equilibration between plasma and its target site, free vs. total drug concentration or chirality. This simple model may be useful for predicting the pharmacodynamics of oxindanac in other species.
Collapse
Affiliation(s)
- J N King
- Ciba-Geigy Animal Health, Centre de Recherches Agricoles, St. Aubin, Switzerland
| |
Collapse
|
29
|
Orrison WW, Champlin AM, Kesterson OL, Hartshorne MF, King JN. MR 'hot nose sign' and 'intravascular enhancement sign' in brain death. AJNR Am J Neuroradiol 1994; 15:913-6. [PMID: 8059660 PMCID: PMC8332192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Three cases of MR with gadopentetate dimeglumine in patients diagnosed with cerebral death are presented. Observation of an MR "hot nose sign" and an "intravascular enhancement sign" provided additional imaging support in the clinical diagnosis of brain death. The MR findings in brain death include: 1) transtentorial and foramen magnum herniation, 2) absent intracranial vascular flow void, 3) poor gray matter/white matter differentiation, 4) no intracranial contrast enhancement, 5) carotid artery enhancement (intravascular enhancement sign), and 6) prominent nasal and scalp enhancement (MR hot nose sign). Additional modalities for confirming brain death are discussed.
Collapse
Affiliation(s)
- W W Orrison
- Department of Radiology, University of New Mexico School of Medicine, Albuquerque 87131-5336
| | | | | | | | | |
Collapse
|
30
|
Brooks JB, Almenoff PL, Daneshvar MI, Johnson AH, Spechart VJ, Basta MT, Unger SE, King JN, Schwartz B. Detection of malignancy-associated metabolites in the sera of cancer patients by electron capture gas chromatography. Br J Cancer 1994; 69:655-62. [PMID: 8142254 PMCID: PMC1968802 DOI: 10.1038/bjc.1994.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
A reliable test that detects malignancy and indicates response to therapy is needed. Frequency-pulsed electron-capture gas-liquid chromatography (FPEC-GLC), a selective analytical technique that is sensitive to 15 fmol quantities of metabolites, was used to analyse derivatised acidic chloroform extracts of sera from patients with biopsy-proven cancer, non-malignant infectious and non-infectious disease, and healthy controls. Two peaks designated P1 and P10, not found in serum from healthy controls (n = 7) or patients with non-malignant disease (n = 85), were detected in biopsy-proven samples (n = 52) from cancer patients. P1 and P10 were later shown by chemical and mass spectral studies to be carboxylic acids. When one or both of these peaks were detected in the sera of non-treated patients they were always associated with malignancy. In patients responding to therapy, a reduction or disappearance of these peaks was observed. Further, it was noted that P10 persisted or increased in sera of patients with progressive cancer not responding to therapy. We conclude that this test has potential in diagnosis and for following the response of the disease to therapy.
Collapse
Affiliation(s)
- J B Brooks
- Respiratory Diseases Branch, Centers for Disease Control, Atlanta, Georgia 30333
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Champlin AM, Rael J, Benzel EC, Kesterson L, King JN, Orrison WW, Mirfakhraee M. Preoperative spinal angiography for lateral extracavitary approach to thoracic and lumbar spine. AJNR Am J Neuroradiol 1994; 15:73-7. [PMID: 8141068 PMCID: PMC8332098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
PURPOSE To establish the safety, efficacy, and value of preoperative angiography in the surgical management of thoracic and lumbar spine disease, in which it is important to avoid injury to the artery of Adamkiewicz or other vessels that supply the spinal cord. METHODS Sixty-one patients were evaluated primarily using digital subtraction angiography, low-osmolar or nonionic contrast agents, selective catheterization limited to the region of disease, and careful angiographic techniques. RESULTS Two minor (small hematomas of the groin) and no major complications of angiography were encountered. Arterial supply to the spinal cord was identified in 22 patients. In 17 patients (77%), the arterial supply was in the region of planned surgery. In each of these patients the surgical approach was altered, either by dictating the use of a posterior surgical approach (four patients) or by altering the side of the lateral extracavitary approach (13 patients). CONCLUSION Spinal angiography is a safe preoperative examination for thoracic and lumbar spine surgery. It is specifically useful when the lateral extracavitary surgical approach to spinal cord decompression and fusion (which predictably interrupts the terminal end-arterial blood supply to the spinal cord, if present) is planned.
Collapse
Affiliation(s)
- A M Champlin
- Department of Radiology, University of New Mexico, School of Medicine, Albuquerque 87131-5336
| | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
The nonsteroidal antiinflammatory drug oxindanac exists as two enantiomers, with most of its pharmacological activity residing in the (S)-isomer. The behavior of its enantiomers was investigated in dogs. Bidirectional inversion occurred in heparinised plasma and blood, with a ratio of enantiomers [S:R] of 7.3:1 being achieved at equilibrium after incubation for 24 h at 37 degrees C. There was no detectable inversion of either isomer in plasma incubated at 4 degrees C for up to 8 h or in aqueous solution at 37 degrees C for up to 36 h. Bidirectional inversion also occurred in vivo, with a ratio of plasma AUC (0 infinity)s [S:R] of 8.1:1. The ratio of enantiomers reached equilibrium within 2 hr following (S)- or rac-oxindanac, and within 8 h following (R)-oxindanac. Elimination t1/2s of the isomers were the same (R, 12.1 h, S, 13.3 h). There were no differences in the ratio of enantiomers following oral or intravenous application, suggesting that a systemic site for inversion was predominant. Although concentrations of the respective isomers were similar at equilibrium following administration of either (R)-, (S)-, or rac-oxindanac, AUC (0 infinity)s differed due to the delay in reaching equilibrium. The extent of inversion to the (S)-isomer was 100, 73.2, and 60.7% after administration of (S)-, rac-, and (R)-oxindanac, respectively. Although pharmacological activity might be equivalent at equilibrium following administration of either (R)-, (S)-, or rac-oxindanac; efficacy at early time points should be superior in the order (S) > racemate > (R).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J N King
- CIBA Animal Health, Centre de Recherches Agricoles, St. Aubin FR, Switzerland
| | | | | | | |
Collapse
|
33
|
King JN. The use of intradermal carrageenan in calves to estimate the dose of oxindanac, a nonsteroidal anti-inflammatory drug. Can J Vet Res 1993; 57:215-22. [PMID: 8269358 PMCID: PMC1263631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
A simple and humane model of inflammation, induced by the intradermal injection of 0.3 mL of sterile 2% carrageenan, was characterized in calves by measuring the volume of skin swelling plus histological analysis of skin biopsies. Carrageenan produced a biphasic increase in skin swelling, with an early edematous response followed by a more chronic cellular infiltrate. The swelling and sensitivity to pressure observed in the early response were suitable for testing the antiedematous and analgesic activity of a new nonsteroidal anti-inflammatory drug (NSAID), oxindanac. Pretreatment with intravenous oxindanac at doses from 0.5 to 8.0 mg/kg reduced the volume of swelling and this reached statistical significance (p < 0.05) at 2 mg/kg. The ED50 and ED90 values for inhibition of the peak swelling volume (4 h) were estimated to be 1 mg/kg and 2 mg/kg, respectively. These compare with an ED90 of 2.0 mg/kg for inhibition of serum TxB2 production, an index of platelet cyclo-oxygenase activity. The dose of oxindanac required for antiedematous activity correlated, therefore, with maximal inhibition of serum TxB2. The analgesic activity of oxindanac reached no clear maximum response, but statistically significant difference (p < 0.05) from placebo was reached with doses of 2 mg/kg and above. It is concluded that intradermal carrageenan produced a simple, humane and useful model for dose estimation of a new NSAID in calves.
Collapse
Affiliation(s)
- J N King
- Ciba-Geigy Animal Health, Centre de Recherches Agricoles, St Aubin, Switzerland
| |
Collapse
|
34
|
King JN, Champlin AM, Ashby RN. Vena cava filters. West J Med 1992; 156:295-6. [PMID: 1595248 PMCID: PMC1003239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
35
|
Abstract
STUDY OBJECTIVES To investigate the role of cranial magnetic resonance (MR) imaging in evaluating patients discharged from the emergency department after minor head injury. DESIGN A prospective blinded cohort study. SETTING University hospital ED. TYPE OF PARTICIPANTS Fifty-eight patients with minor head injury who were discharged from the ED with written head injury instructions. Patients admitted to the hospital were excluded. INTERVENTIONS Ultra-low-field cranial MR scans were performed on patients within 24 hours of discharge. Scans were read blindly by two radiologists. MEASUREMENTS AND MAIN RESULTS Fisher's exact test was used to compare symptoms in patients with abnormal and normal MR scans. There was no significant difference in symptoms between patients with abnormal and those with normal scans (P greater than .10). The proportion of abnormal MR scans was analyzed using the binomial distribution. Six of the 58 patients (10.3%) had traumatic intracranial abnormalities (proportion, 0.103; SD, 0.04; 95% CI, 0.04-0.21). Three had cortical contusions, and three had small subdural hematomas. Two of the six patients with abnormal MR scans, both with small subdural hematomas, had normal computed tomography scans. CONCLUSION Ten percent of patients discharged from the ED after minor head injury had abnormal ultra-low-field cranial MR scans. Additional research is needed to establish the clinical importance of this unexpected observation.
Collapse
Affiliation(s)
- D Doezema
- Division of Emergency Medicine, University of New Mexico School of Medicine, Albuquerque 87131
| | | | | | | | | |
Collapse
|
36
|
Abstract
The hazard of magnetic resonance (MR) imaging at low field strength (0.06 T) was examined by using both in vitro and in vivo animal experiments. Ferromagnetic fragments, 0.25-2.2 mm in diameter, were placed in vitreous humor obtained from excised cow eyes and in rabbit eyes. The magnetic field strength at which motion occurred was measured for each fragment size. Two types of motion, rotation and translation, were observed. The authors found that fragments that could not be seen on plain radiographs did not appear to move enough to be a significant ocular hazard during MR imaging at a field strength of 0.06 T.
Collapse
Affiliation(s)
- C A Kelsey
- Department of Radiology, University of New Mexico School of Medicine, Albuquerque 87131-5336
| | | | | | | | | | | |
Collapse
|
37
|
Snyder RD, King JN, Keck GM, Orrison WW. MR imaging of the spinal cord in 23 subjects with ALD-AMN complex. AJNR Am J Neuroradiol 1991; 12:1095-8. [PMID: 1763733 PMCID: PMC8331466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Twenty-three subjects from two family groups with the adrenoleukodystrophy (ALD)-adrenomyeloneuropathy (AMN) complex were examined with MR imaging at 1.5 T to determine the presence and extent of brain and spinal cord abnormalities. Nineteen individuals were identified as having ALD or AMN, or as having carrier status on the basis of pedigree analysis and/or evaluation of serum very-long-chain fatty acids. In addition to the expected intracranial white matter changes for this disorder, decreased spinal cord diameter was found in seven (30%) of the 23 subjects. In three of these cases, atrophy was limited to the thoracic spinal cord, while atrophy of both the cervical and thoracic cord was identified in four patients. Two patients who did not have MR imaging of the spine were found to have spinal cord atrophy at autopsy. The finding of decreased spinal cord diameter on MR examinations in individuals who are heterozygous for ALD-AMN, in patients with ALD or AMN, and in asymptomatic ALD-AMN patients may represent a new anatomic marker for the variable clinical presentations of this condition. In addition to cranial MR examination, MR imaging of the spine may be indicated in patients with suspected ALD or AMN, or in women with carrier status.
Collapse
Affiliation(s)
- R D Snyder
- Department of Neurology, University of New Mexico School of Medicine, Albuquerque 87131-5281
| | | | | | | |
Collapse
|
38
|
Abstract
Post operative ileus (POI) is a common and serious complication of colic surgery in the horse. There is a high correlation between the incidence of POI and the presence of ischaemic bowel, suggesting a role for endotoxin. 0.1 micrograms/kg endotoxin was administered intravenously to six ponies with chronically implanted gastrointestinal electromechanical recording devices. It produced profound disruption of normal fasting bowel motility patterns, with an inhibition of gastric contraction amplitude and rate, left dorsal colon contraction product and small colon spike rate. In the small intestine an increase in abnormally arranged regular activity and a decrease in irregular activity was observed. There was no significant prolongation in stomach to anus transit time as assessed by the passage of plastic spheres. The bowel motility patterns induced by endotoxin could be mimicked by the intravenous infusion of PGE2 and less potently by PGI2 (prostacyclin), but not by PGF2 alpha. This study provides evidence that systematic endotoxin present in clinical cases of colic may play a role in the pathogenesis of equine ileus. The acute effects of endotoxin on bowel motility appear to be mediated indirectly by prostaglandins, and the inhibitory effects may be mediated mainly by PGE2.
Collapse
Affiliation(s)
- J N King
- Department of Surgery, Royal Veterinary College, North Mymms, Hertfordshire, England
| | | |
Collapse
|
39
|
King JN, Gerring EL. Antagonism of endotoxin-induced disruption of equine gastrointestinal motility with the platelet-activating factor antagonist WEB 2086. J Vet Pharmacol Ther 1990; 13:333-9. [PMID: 2287025 DOI: 10.1111/j.1365-2885.1990.tb00786.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The effect of pre-treatment with a selective platelet-activating factor (PAF) antagonist, WEB 2086, on the actions of low-dose endotoxin was evaluated in ponies prepared with gastrointestinal strain gauges. Endotoxin (0.1 microgram/kg i.v.) produced a marked reduction in gastric contraction amplitude and rate, and an increased frequency and reduced duration of jejunal phase III activity fronts (AFs). WEB 2086 (6.6 mg/kg) administered i.v. 10 min before the endotoxin, produced significant antagonism (P less than 0.001) of the effect of endotoxin on gastric contraction amplitude and rate. The combination of WEB 2086 and endotoxin produced gastric contractions of significantly (P less than 0.01) higher frequency than in the control studies. WEB 2086 also reduced endotoxin-induced abnormal phase III AFs in the jejunum and increases in heart rate and packed cell volume. These results provide evidence that endogenous PAF plays a role in mediating the acute effects of endotoxin on equine gastrointestinal motility.
Collapse
Affiliation(s)
- J N King
- Department of Surgery and Obstetrics, Royal Veterinary College, North Mymms, Herts, UK
| | | |
Collapse
|
40
|
Affiliation(s)
- J N King
- Department of Surgery and Obstetrics, Royal Veterinary College, Hatfield, Herts
| | | | | |
Collapse
|
41
|
Abstract
Fifty-one arteriograms were obtained outside of the radiology department with portable digital subtraction angiographic equipment. Thirty-five studies were performed in the emergency room, 12 in the operating room, and four in the intensive care unit. There was a significant decrease in the time interval from arrival in the emergency room to arteriogram completion for examinations performed in the emergency room with portable equipment, compared with those performed in the radiology department. One of the 51 examinations yielded questionable results and was repeated with the conventional screen-film technique. Accurate angiographic diagnoses can be obtained by means of portable equipment in a variety of hospital locations.
Collapse
Affiliation(s)
- J N King
- Department of Radiology, University of New Mexico School of Medicine, Albuquerque 87131
| | | | | | | | | | | |
Collapse
|
42
|
Abstract
Characteristic motility patterns were seen throughout the gastrointestinal tract in a pony prepared chronically with electromechanical recording devices after developing a simple obstruction of the small intestine. Gross distension of the stomach with fluid produced loss of gastric contractile activity and a chaotic electrogram. These changes were reversed instantaneously when the stomach was decompressed. In the jejunum, proximal to the obstruction, the unique 'colic motor complex' was observed with contractions of longer duration arranged in characteristic pulses of activity. The left dorsal colon showed continuous hyperactivity and the small colon remained active. Abnormal motility patterns occurring secondary to a small intestinal obstruction could play a role in the aetiology of small and large intestinal disorders.
Collapse
Affiliation(s)
- J N King
- Department of Surgery and Obstetrics, Royal Veterinary College, North Mymms, Herts
| | | |
Collapse
|
43
|
Abstract
Post operative ileus is a serious complication of abdominal surgery in horses and there is evidence that endotoxin plays a significant role in its pathogenesis. Pre-treatment with intravenous (i.v.) flunixin (1.1 mg/kg bodyweight [bwt]) or phenylbutazone (4.4 mg/kg bwt) significantly antagonised the acute disruption of gastric, small intestinal and large intestinal motility induced by 0.1 microgram/kg bwt i.v. endotoxin in ponies implanted with gastrointestinal strain gauges. Phenylbutazone was more effective than flunixin and this was significant (P < 0.01) for the stomach and left dorsal colon. Both drugs reduced the acute systemic side-effects of the endotoxin and flunixin was slightly more effective than phenylbutazone in antagonising the cardiovascular effects. These results suggest that the acute effects of endotoxin on bowel motility are mediated at least in part by a cyclooxygenase dependent pathway. Flunixin and phenylbutazone showed a relative selectivity for the cardiovascular and gastrointestinal effects of endotoxin, respectively. Phenylbutazone may be of use clinically in acute colic cases, antagonising the disruptive effects of endotoxin on bowel motility, without entirely blocking the cardiovascular effects which can indicate that the patient has a condition requiring surgery.
Collapse
Affiliation(s)
- J N King
- Department of Surgery and Obstetrics, Royal Veterinary College, North Mymms, Hertfordshire
| | | |
Collapse
|
44
|
Abstract
Cisapride and domperidone were both effective in restoring electrical and mechanical activity, coordination between gastric and small intestinal activity cycles and the stomach to anus transit time in three ponies in which post operative ileus was induced experimentally. Cisapride (0.1 mg/kg bodyweight intramuscularly) for three to eight doses prevented idiopathic post operative ileus in 22 clinical cases requiring colic surgery. The only side effects after cisapride were increased bowel sounds and slight, transient sounds of discomfort. No adverse side effects were seen in 16 cases following anastomosis or enterotomy. Cisapride appears safe and effective in the prophylaxis of equine post operative ileus.
Collapse
Affiliation(s)
- E L Gerring
- Department of Surgery and Obstetrics, Royal Veterinary College, North Mymms, Herts
| | | |
Collapse
|
45
|
Abstract
Dopamine was infused intravenously (1, 5 and 10 micrograms/kg/min) for 60 min in three fasted ponies. A dose-dependent increase in heart rate occurred that was rapid in onset and termination at the start and end of the infusions, respectively. Dose-dependent changes in gastric and small intestinal motility were observed. An initial marked inhibition of gastric contraction amplitude was followed by a secondary prolonged period of activity. At the same time the small intestine showed a prolonged period of irregular activity (phase II) and a marked increase in the interval between successive phase IIIs. The left dorsal colon and small colon exhibited variable responses. The normal fasting motility pattern was therefore disrupted by dopamine biphasically, an initial inhibition of the stomach being followed by a period of increased activity in the stomach and small intestine which resembled the postprandial motility pattern. Although the cardiovascular effects of dopamine were transient, the increases in gastrointestinal motility persisted long after the infusion was terminated.
Collapse
Affiliation(s)
- J N King
- Department of Surgery & Obstetrics, Royal Veterinary College, North Mymms, Herts, U.K
| | | |
Collapse
|
46
|
Abstract
The effect of cisapride was evaluated on the normal fasting bowel motility of four ponies with chronically implanted electromechanical transducers. Cisapride was infused over 60-min periods at 0.05 mg/kg (n = 4), 0.1 mg/kg (n = 5) and 0.25 mg/kg (n = 5). It produced marked and prolonged increases in electrical and mechanical activity at all sites examined. In the stomach there was increased total contraction activity with increased contraction amplitude and a slight reduction in rate. In the small intestine there was an increase in irregular (phase II) activity with an increase in number and amplitude of contractions and a decrease in the number of regular (phase III) activity fronts. There was a decrease in the number of phase III fronts that spread distally from the jejunum to the ileum. The phase II activity was coordinated temporally with prolonged activity in the stomach. Cisapride increased electrical and contractile activity in the left dorsal colon with increased contraction amplitude and an increase in electrical activity in the small colon. In the stomach and small intestine cisapride produced dose-dependent increases in activity but in the left dorsal and small colon the intermediate dose (0.1 mg/kg) produced the largest and most consistent responses. Side-effects observed were increased bowel sounds and frequency of defaecation, a slight increase in heart rate and transient signs of discomfort at the highest (0.25 mg/kg) dose rate.
Collapse
Affiliation(s)
- J N King
- Department of Surgery & Obstetrics, Royal Veterinary College, North Mymms, Herts, U.K
| | | |
Collapse
|
47
|
Davis M, Eckel CG, King JN, Waterman R. Radionuclide, computed tomography, and digital imaging of duplicated inferior vena cava. Radiat Med 1988; 6:256-8. [PMID: 3249815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Duplication of the inferior vena cava (IVC) is not an uncommon vascular anomaly. We describe here the appearance of double IVC by radionuclide angiography, computed tomography (CT) scan, and digital angiography. It is important to confirm the presence of duplicated IVC, which is usually first seen on CT scan, because patients undergoing certain surgical procedures would be at greater risk for injury to the IVC as well as other complications.
Collapse
Affiliation(s)
- M Davis
- Department of Radiology, School of Medicine, University of New Mexico, Albuquerque
| | | | | | | |
Collapse
|
48
|
Abstract
The Limulus amoebocyte lysate assay was used to test for the presence of endotoxin in 37 clinical cases of equine colic. Positive plasma titres were detected in 10 cases and the presence of endotoxin was significantly correlated with a high heart rate, a high packed cell volume and a poor prognosis. High levels of endotoxin were detected in gut contents taken from several sites in the gastrointestinal tract of normal horses.
Collapse
Affiliation(s)
- J N King
- Department of Surgery, Royal Veterinary College, North Mymms, Hatfield, Hertfordshire
| | | |
Collapse
|
49
|
Abstract
We have presented a case of massive scrotal hernia containing the entire mesenteric small bowel and the entire colon. Review of the literature reveals that such extensive hernias are rare and that their surgical repair is often difficult because of loss of domain.
Collapse
|
50
|
Shah RR, Spinazzola AJ, King JN. Clinical experience with expanded polytetrafluoroethylene (Gore-Tex) grafts for femoropopliteal arterial bypass. Am J Surg 1980; 139:330-2. [PMID: 7362001 DOI: 10.1016/0002-9610(80)90287-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Thirty-seven grafts of expanded polytetrafluoroethylene were implanted in 28 patients in whom autogeneous saphenous vein was not available, either for symptoms of severe claudication or limb salvage. The length of follow-up ranges from 8 to 28 months . The patency rate is 86.9 percent for the patients with severe claudication and 71.4 percent in the limb salvage group; the overall patency rate is 81 percent. We believe that expanded polytetrafluoroethylene is a good prosthetic substitute when autogenous vein is unavailable.
Collapse
|